Advertisement
Advertisement
ALKS
Alkermes Inc. plc
46.53
USDSponsored
-0.50
-1.06%
Nov 16, 16:00 UTC -5
Closed
After-Market
46.53
0.00
+0.01%
Alkermes Inc. plc (ALKS) Earnings
ALKS Earnings Reports
Positive Surprise Ratio
ALKS beat 35 of 44 last estimates.
80%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$470.12M
/-$0.17
Implied change from Q3 26 (Revenue/ EPS)
-2.09%
/-288.89%
Implied change from Q4 25 (Revenue/ EPS)
+22.25%
/-160.71%
Alkermes Inc. plc earnings per share and revenue
On Nov 03, 2026, ALKS reported earnings of 0.09 USD per share (EPS) for Q3 26, beating the estimate of -0.07 USD, resulting in a 225.00% surprise. Revenue reached 480.13 million, compared to an expected 472.88 million, with a 1.53% difference. The market reacted with a +1.78% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.17 USD, with revenue projected to reach 470.12 million USD, implying an decrease of -288.89% EPS, and decrease of -2.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

ALX Oncology Holdings Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-6.31%

Genelux Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.22%

Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%

Eloxx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.58
Actual
-$0.49
Surprise
+16.70%

Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%

LeonaBio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.73
Actual
-$0.89
Surprise
-20.35%

Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%

CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
FAQ
What were Alkermes Inc. plc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Alkermes Inc. plc reported EPS of $0.09, beating estimates by 225%, and revenue of $480.13M, 1.53% above expectations.
How did the market react to Alkermes Inc. plc's Q3 2026 earnings?
The stock price moved up 1.78%, changed from $44.89 before the earnings release to $45.69 the day after.
When is Alkermes Inc. plc expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Alkermes Inc. plc's next earnings report?
Based on --
analysts, Alkermes Inc. plc is expected to report EPS of -$0.17 and revenue of $470.12M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.